PHGDH and hepatocellular carcinoma: Accumulating studies have identified multiple potential drivers of sorafenib resistance in HCC, such as phosphoglycerate dehydrogenase (PHGDH), shugoshin 1 (SGOL1), and metaxin 1 (MTX1) [19, 21, 22].